CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
Clinical trial NCT01636882 · COMPLETED
Trial details
- NCT number
- NCT01636882
- Sponsor
- Viralytics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-07-03
- Primary completion
- 2016-04-06
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.